Table 3.
Echocardiographic parameters over a 1-year follow-up period.
| Spironolactone continuation (n = 30) | Spironolactone withdrawal (n = 40) | P (ANCOVA) | |
|---|---|---|---|
| LVEF, % | 0.23 | ||
| Visit 1 | 46 ± 7 | 45 ± 6 | |
| Visit 2 | 51 ± 7 | 49 ± 8 | |
| LVEDD, mm | 0.56 | ||
| Visit 1 | 61 ± 8 | 59 ± 6 | |
| Visit 2 | 58 ± 6 | 58 ± 6 | |
| LVESD, mm | 0.91 | ||
| Visit 1 | 46 ± 8 | 45 ± 6 | |
| Visit 2 | 43 ± 6 | 43 ± 7 | |
| LVEDV, ml | 0.52 | ||
| Visit 1 | 195 ± 57 | 176 ± 39 | |
| Visit 2 | 171 ± 46 | 176 ± 40 | |
| LVESV, ml | 0.82 | ||
| Visit 1 | 104 ± 42 | 95 ± 28 | |
| Visit 2 | 85 ± 31 | 90 ± 30 | |
| LVEDVi, ml/m 2 | 0.57 | ||
| Visit 1 | 108 ± 31 | 98 ± 19 | |
| Visit 2 | 95 ±24 | 99 ± 22 | |
| LVESVi, ml/m 2 | 0.77 | ||
| Visit 1 | 58 ± 24 | 52 ± 16 | |
| Visit 2 | 47 ± 17 | 51 ± 17 | |
| LVM, g | 0.08 | ||
| Visit 1 | 240 ± 70 | 230 ± 79 | |
| Visit 2 | 206 ± 53 | 225 ± 78 | |
| LVMi, g/m 2 | 0.04 | ||
| Visit 1 | 133 ± 37 | 127 ± 34 | |
| Visit 2 | 114 ± 28 | 125 ± 36 | |
| Log NT-proBNP concentration, pg/L | 0.09 | ||
| Visit 1 | 2.85 ± 0.55 | 2.81 ± 0.63 | |
| Visit 2 | 2.05 ± 0.61 | 2.58 ± 0.83 |
Data are expressed as mean ± SD. Difference of each echocardiographic parameter at visit 2 was analyzed using regression analysis of covariance (ANCOVA) adjusted for the measurement at visit 1.
LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEDVi, LVEDV indexed by body surface area; LVESVi, LVESV indexed by body surface area; LVM, left ventricular mass; LVMi, LVM indexed by body surface area; NT-proBNP, N-terminal pro-B-type natriuretic peptide.